Literature DB >> 23161119

Influence of osteopontin silencing on survival and migration of lung cancer cells.

B Polat1, G Wohlleben, A Katzer, C S Djuzenova, A Technau, M Flentje.   

Abstract

BACKGROUND AND
PURPOSE: Osteopontin (OPN) is a multifunctional protein overexpressed in many cancers and is involved in tumor progression and metastasis. In lung cancer, elevated OPN expression is associated with an unfavorable prognosis. Therefore, inhibition of OPN is an attractive approach for improving survival.
MATERIALS AND METHODS: We used siRNA to specifically downregulate OPN expression in A549 lung cancer cells. OPN silencing was evaluated with quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for mRNA levels and with Western blotting for protein levels. Effects on cell proliferation were measured by cell counting. The influence on tumor cell migration was detected using a modified Boyden chamber. Changes in cell cycle distribution were assessed by flow cytometry. Using the colony formation assay, we determined changes in radiosensitivity.
RESULTS: A specific and effective downregulation of OPN expression was detected in both RNA and protein levels. Cell proliferation and cell migration were significantly reduced by OPN silencing after 24 h and the effects were further increased by the addition of irradiation. The cell cycle distribution showed a reduction in S phase and an increase in cells arrested in both G(0)/G(1) and G(2)/M phases. Specific enhancement of radiosensitivity was clearly shown after OPN knockdown.
CONCLUSION: The combination of OPN silencing and irradiation showed a synergistic effect leading to reduced cell survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23161119     DOI: 10.1007/s00066-012-0238-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  25 in total

1.  Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer.

Authors:  Bai Zhao; Tiemin Sun; Fanjuan Meng; Aibing Qu; Chunling Li; Hui Shen; Yu Jin; Wenxin Li
Journal:  J Cancer Res Clin Oncol       Date:  2011-01-05       Impact factor: 4.553

2.  Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.

Authors:  Chandra M V Goparaju; Harvey I Pass; Justin D Blasberg; Nathalie Hirsch; Jessica S Donington
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

3.  Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.

Authors:  Matthias Bache; Rolf Reddemann; Harun M Said; Hans-Jürgen Holzhausen; Helge Taubert; Axel Becker; Thomas Kuhnt; Gabriele Hänsgen; Jürgen Dunst; Dirk Vordermark
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-10-23       Impact factor: 7.038

4.  Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry.

Authors:  Jiang Wu; Pooja Pungaliya; Eugenia Kraynov; Brian Bates
Journal:  Biomarkers       Date:  2011-12-22       Impact factor: 2.658

5.  Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models.

Authors:  Slavka Lukacova; Jens Overgaard; Jan Alsner; Michael R Horsman
Journal:  Radiother Oncol       Date:  2006-08-21       Impact factor: 6.280

6.  Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells.

Authors:  Harun M Said; Astrid Katzer; Michael Flentje; Dirk Vordermark
Journal:  Radiother Oncol       Date:  2005-08       Impact factor: 6.280

7.  Quantitative assessment of hypoxia subtypes in microcirculatory supply units of malignant tumors using (immuno-)fluorescence techniques.

Authors:  Constantin-Alin Maftei; Christine Bayer; Kuangyu Shi; Sabrina T Astner; Peter Vaupel
Journal:  Strahlenther Onkol       Date:  2011-03-24       Impact factor: 3.621

8.  An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.

Authors:  Quynh-Thu Le; Eunice Chen; Ali Salim; Hongbin Cao; Christina S Kong; Richard Whyte; Jessica Donington; Walter Cannon; Heather Wakelee; Robert Tibshirani; John D Mitchell; Donna Richardson; Ken J O'Byrne; Albert C Koong; Amato J Giaccia
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

9.  Matricellular proteins: a sticky affair with cancers.

Authors:  Han Chung Chong; Chek Kun Tan; Royston-Luke Huang; Nguan Soon Tan
Journal:  J Oncol       Date:  2012-02-09       Impact factor: 4.375

10.  Normal expression of DNA repair proteins, hMre11, Rad50 and Rad51 but protracted formation of Rad50 containing foci in X-irradiated skin fibroblasts from radiosensitive cancer patients.

Authors:  C Djuzenova; B Mühl; R Schakowski; U Oppitz; M Flentje
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more
  5 in total

1.  Studies on the role of osteopontin-1 in endometrial cancer cell lines.

Authors:  J C Hahne; S R Meyer; P Kranke; J Dietl; M Guckenberger; B Polat; A Hönig
Journal:  Strahlenther Onkol       Date:  2013-10-16       Impact factor: 3.621

2.  Osteopontin expression in co-cultures of human squamous cell carcinoma-derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation.

Authors:  Lucas Novaes Teixeira; Larissa Moreira Spinola de Castro Raucci; Gabriela Caroline Alonso; Ricardo Della Coletta; Adalberto Luiz Rosa; Paulo Tambasco de Oliveira
Journal:  Tumour Biol       Date:  2016-06-16

3.  Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines.

Authors:  Gisela Wohlleben; Agmal Scherzad; Antje Güttler; Dirk Vordermark; Sebastian Kuger; Michael Flentje; Buelent Polat
Journal:  Radiat Oncol       Date:  2015-08-12       Impact factor: 3.481

4.  Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.

Authors:  Bülent Polat; Philipp Kaiser; Gisela Wohlleben; Thomas Gehrke; Agmal Scherzad; Matthias Scheich; Uwe Malzahn; Thomas Fischer; Dirk Vordermark; Michael Flentje
Journal:  BMC Cancer       Date:  2017-01-03       Impact factor: 4.430

Review 5.  Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight.

Authors:  Anne-Sophie Lamort; Ioanna Giopanou; Ioannis Psallidas; Georgios T Stathopoulos
Journal:  Cells       Date:  2019-08-02       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.